Rafael Holdings, Inc. (NYSE:RFL) Short Interest Update

Posted by Brenda Bartman on Sep 17th, 2026

Rafael Holdings, Inc. (NYSE:RFL – Get Free Report) was the target of a large increase in short interest in August. As of August 31st, there was short interest totaling 789,900 shares, an increase of 97.7% from the August 15th total of 399,613 shares. Currently, 2.3% of the company’s stock are short sold. Based on an average daily trading volume, of 124,437 shares, the days-to-cover ratio is presently 6.3 days.

Rafael Stock Performance

Shares of NYSE RFL traded up $0.04 during midday trading on Thursday, reaching $2.10. 31,833 shares of the company traded hands, compared to its average volume of 125,924. The firm has a market cap of $109.41 million, a PE ratio of -3.09 and a beta of 0.40. Rafael has a 12 month low of $1.12 and a 12 month high of $3.96. The stock’s 50-day simple moving average is $2.19 and its 200-day simple moving average is $1.84.

Institutional Investors Weigh In On Rafael

A hedge fund recently bought a new stake in Rafael stock. Kahn Brothers Group Inc. acquired a new stake in Rafael Holdings, Inc. (NYSE:RFL – Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 150,493 shares of the company’s stock, valued at approximately $494,000. Kahn Brothers Group Inc. owned about 0.29% of Rafael as of its most recent filing with the SEC. 11.30% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Wall Street Zen raised shares of Rafael to a “hold” rating in a research report on Saturday, July 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rafael in a research report on Tuesday, August 25th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Rafael presently has a consensus rating of “Sell”.

Get Our Latest Research Report on RFL

Rafael Company Profile

(Get Free Report)

Rafael Holdings, Inc is a diversified holding company focused primarily on commercial real estate and life sciences. The company’s real estate activities include ownership and management of commercial properties, with a focus on properties in the New York metropolitan area and other strategic locations.

Through its life sciences investments and subsidiaries, Rafael Holdings has supported the development of oncology treatments and other pharmaceutical technologies. Its best-known biotechnology subsidiary, Rafael Pharmaceuticals, developed investigational cancer therapies, including devimistat, a treatment designed to target cancer-cell metabolism.